SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 170.68 |
| Enterprise Value ($M) | n/a |
| Book Value ($M) | 94.80 |
| Book Value / Share | 0.96 |
| Price / Book | n/a |
| NCAV ($M) | 35.85 |
| NCAV / Share | 0.36 |
| Price / NCAV | n/a |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -0.52 |
| Return on Assets (ROA) | -0.31 |
| Return on Equity (ROE) | -0.36 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 1.53 |
| Current Ratio | 1.53 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 152.13 |
| Assets | 211.08 |
| Liabilities | 116.28 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 27.31 |
| Operating Income | -52.38 |
| Net Income | -50.92 |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | 65.84 |
| Cash from Investing | -105.29 |
| Cash from Financing | -1.12 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G/A | AFFiRiS AG | 6.50 | -2.28 | |
| 13G/A | Biotechnology Value Fund L P | 19.70 | 33.98 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 21,520 | 62,436 | 34.47 | |
| 8,470 | 49,178 | 17.22 | |
| 8,990 | 39,669 | 22.66 | |
| 45,151 | 129,095 | 34.98 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| ACET – Adicet Bio, Inc. | ACRV – Acrivon Therapeutics, Inc. |
| ADMA – ADMA Biologics, Inc. |
Financial data and stock pages provided by
Fintel.io